Related references
Note: Only part of the references are listed.2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
Rimei Nishimura et al.
BMJ OPEN (2019)
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States
Reema Mody et al.
DIABETES OBESITY & METABOLISM (2019)
Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment
Reema Mody et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Twelve-year trends of increasing overweight and obesity in patients with diabetes: the Shiga Diabetes Clinical Survey
Itsuko Miyazawa et al.
ENDOCRINE JOURNAL (2018)
Japanese Clinical Practice Guideline for Diabetes 2016
Masakazu Haneda et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
Marco Orsini Federici et al.
DIABETES THERAPY (2018)
Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
Marco Orsini Federici et al.
DIABETES THERAPY (2018)
Penetration of new antidiabetic medications in East Asian countries and the United States: A cross-national comparative study
Kiyoshi Kubota et al.
PLOS ONE (2018)
Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes
Maria Yu et al.
CLINICAL THERAPEUTICS (2017)
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
Ginger S. Carls et al.
DIABETES CARE (2017)
Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States
Jennifer Cai et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Comparison of clinical characteristics in patients with type2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists
Kazuya Fujihara et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis
Thomas Wilke et al.
DIABETES THERAPY (2016)
Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis
Thomas Wilke et al.
DIABETES THERAPY (2016)
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
M. Odawara et al.
DIABETES OBESITY & METABOLISM (2016)
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study
J. Miyagawa et al.
DIABETES OBESITY & METABOLISM (2015)
Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
Y. G. Kim et al.
DIABETES OBESITY & METABOLISM (2014)
Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
Stuart A. Ross et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Chrysi Koliaki et al.
Diabetes Therapy (2011)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
The status of diabetes control and antidiabetic drug therapy in Japan - A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)
Masashi Kobayashi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes
M Fukushima et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Share Paper
